Want to see CORT full AI Analyst Report?
Top Page
Corcept Therapeutics
(NASDAQ:CORT)
Select Model
Select Model
Rating:79Outperform
Price Target:
$135.00
▲(41.57% Upside)
Action:Reiterated
Date:07/31/26
The score is driven primarily by strong financial footing (very low leverage and solid cash generation) and clear technical strength with the stock trading well above all key moving averages. This is balanced by elevated valuation risk (very high P/E) and recent profitability pressure, though the latest earnings call was supportive due to raised guidance and strong pipeline/commercial momentum despite near-term loss and execution risks.
Positive Factors
Conservative Balance Sheet
Extremely low leverage and a large equity base provide durable financial flexibility to fund product launches, expand specialty pharmacy networks, and support multiple late‑stage trials without reliance on external financing. This reduces refinancing and covenant risks over the next 2–6 months.
Negative Factors
Profitability Compression
Sharp margin deterioration reflects elevated launch and operating spend that may persist while scaling oncology and commercialization efforts. Even with revenue growth, compressed margins reduce earnings resilience and could restrain long‑term return metrics and cash flow expansion until operating leverage is realized.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low leverage and a large equity base provide durable financial flexibility to fund product launches, expand specialty pharmacy networks, and support multiple late‑stage trials without reliance on external financing. This reduces refinancing and covenant risks over the next 2–6 months.
Read all positive factors
Corcept Therapeutics Key Performance Indicators (KPIs)
Any
Research & Development Expense Breakdown
Allocation of R&D spending across programs and trial stages reveals how Corcept is prioritizing its pipeline—whether cash is focused on late‑stage clinical trials that could produce near‑term approvals and revenue, or on early discovery that points to longer‑term growth. Changes in the mix and absolute R&D spend also signal the company’s cash burn and financing needs, the surface area for regulatory and clinical risk, and how management balances short‑term commercial support with long‑term drug development.
Allocation of R&D spending across programs and trial stages reveals how Corcept is prioritizing its pipeline—whether cash is focused on late‑stage clinical trials that could produce near‑term approvals and revenue, or on early discovery that points to longer‑term growth. Changes in the mix and absolute R&D spend also signal the company’s cash burn and financing needs, the surface area for regulatory and clinical risk, and how management balances short‑term commercial support with long‑term drug development.
Data provided by:
The Fly
The FlyCorcept Therapeutics (CORT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.37B
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)220.1
Beta (1Y)0.52
Revenue Growth16.02%
EPS Growth-59.24%
CountryUS
Employees730
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.52
Shares Outstanding108,098,400
10 Day Avg. Volume1,209,033
30 Day Avg. Volume1,056,039
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$135.25Price Target Upside41.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)2.03
Revenue Forecast (FY)$1.10B
Corcept Therapeutics Business Overview & Revenue Model
Company Description
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsyc...
How the Company Makes Money
Corcept primarily makes money by selling its FDA-approved product Korlym (mifepristone) in the United States. Revenue is generated from product sales to customers in the pharmaceutical distribution channel (e.g., specialty pharmacy and/or wholesal...
Corcept Therapeutics Earnings Call Summary
Earnings Call Date:Jul 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call highlights robust commercial momentum and meaningful clinical and regulatory progress: strong Q2 financials (+32% revenue growth), a fast and well‑covered Lifyorli launch with survival data supporting uptake, record Korlym prescribing driven by shifting clinical awareness, and multiple near‑term trial readouts. Offsetting these positives are residual regulatory risk for relacorilant (prior CRL, PDUFA Dec 17, 2026), tolerability concerns and mixed statistical significance in early ALS results, and the usual clinical/regulatory execution risks across the pipeline. On balance, the positive financial performance, rapid oncology launch, and pipeline catalysts outweigh the noted risks.Positive Updates
Strong Revenue Growth
Total revenue for Q2 2026 was $256.0 million, a 32% increase year-over-year. Korlym + authorized generic revenue were $208.6 million and Lifyorli generated $47.6 million in its first quarter of availability.
Negative Updates
Earlier Complete Response Letter for Relacorilant
The FDA issued a CRL at the end of last year for relacorilant, reflecting prior regulatory concerns. Although the company resubmitted analyses and received acceptance, regulatory risk remains until the Dec 17, 2026 PDUFA decision.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Total revenue for Q2 2026 was $256.0 million, a 32% increase year-over-year. Korlym + authorized generic revenue were $208.6 million and Lifyorli generated $47.6 million in its first quarter of availability.
Read all positive updates
Company Guidance
Management raised 2026 revenue guidance to $1.1–$1.2 billion; reported Q2 revenue of $256 million (up 32% YoY) with Korlym and authorized generic revenue of $208.6 million and Lifyorli product revenue of $47.6 million in its first quarter, net income of $43 million (vs. $35M prior year), cash and investments of $545 million at June 30, and operating expenses flat to Q1; they forecast the Cushing’s syndrome business to reach at least $2 billion in annual revenue by the end of the decade (and, per the call, $3–$5 billion with relacorilant), see Lifyorli growing to more than $1 billion annually in the U.S., noted >1,300 patients have started Lifyorli with >1,000 unique prescribers and formal coverage for >70% of combined lives, and highlighted upcoming readouts (BELLA/STELLA/TRIDENT by end of next year, MONARCH and DAZZLE this year) including clinical signals such as ROSELLA’s 35% reduction in risk of death (HR 0.65, p=0.04) and DAZZLE’s 84% 1‑year mortality reduction (p=0.09) and 87% at year two (p<0.01).Corcept Therapeutics Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
92
Very Positive
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 830.81M | 761.41M | 675.04M | 482.38M | 401.86M | 365.98M |
| Gross Profit | 816.73M | 748.43M | 664.16M | 475.89M | 396.47M | 360.70M |
| EBITDA | 28.79M | 68.35M | 162.83M | 125.60M | 117.45M | 127.95M |
| Net Income | 54.90M | 99.65M | 139.73M | 106.14M | 101.42M | 112.51M |
Balance Sheet | ||||||
| Total Assets | 888.70M | 836.65M | 840.55M | 621.52M | 583.43M | 423.76M |
| Cash, Cash Equivalents and Short-Term Investments | 308.20M | 372.15M | 383.33M | 368.22M | 431.67M | 223.53M |
| Total Debt | 9.42M | 6.11M | 6.94M | 151.00K | 1.14M | 526.00K |
| Total Liabilities | 182.93M | 188.85M | 160.96M | 114.81M | 81.59M | 47.95M |
| Stockholders Equity | 705.78M | 647.80M | 679.59M | 506.70M | 501.84M | 375.81M |
Cash Flow | ||||||
| Free Cash Flow | 106.92M | 141.78M | 195.90M | 126.90M | 119.91M | 167.42M |
| Operating Cash Flow | 109.70M | 142.00M | 198.07M | 127.04M | 120.32M | 167.89M |
| Investing Cash Flow | -21.90M | 69.76M | -177.60M | 90.91M | -114.33M | 136.13M |
| Financing Cash Flow | -78.91M | -220.37M | -28.35M | -148.72M | -17.28M | -302.59M |
Corcept Therapeutics Technical Analysis
Positive
95.36
Price Trends
92.88
Positive
71.58
Positive
63.62
Positive
Market Momentum
6.55
Positive
64.77
Neutral
59.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Positive. The current price of 95.36 is below the 20-day moving average (MA) of 104.82, above the 50-day MA of 92.88, and above the 200-day MA of 63.62, indicating a bullish trend. The MACD of 6.55 indicates Positive momentum. The RSI at 64.77 is Neutral, neither overbought nor oversold. The STOCH value of 59.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CORT.
Corcept Therapeutics Risk Analysis
Corcept Therapeutics disclosed 29 risk factors in its most recent earnings report. Corcept Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corcept Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $12.37B | 220.13 | 8.37% | ― | 16.02% | -59.24% | |
78 Outperform | $15.90B | 16.12 | 21.37% | ― | 12.59% | ― | |
58 Neutral | $43.66B | -22.99 | -96.44% | ― | ― | -95.67% | |
56 Neutral | $7.95B | -37.13 | -80.48% | ― | 53.51% | -3.31% | |
54 Neutral | $3.95B | -40.74 | -8.70% | ― | 59.59% | 71.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $11.19B | -56.98 | -255.60% | ― | 56.87% | 25.87% |
* Healthcare Sector Average
CORT
Corcept Therapeutics
114.47
42.71
59.52%
JAZZ
Jazz Pharmaceuticals
244.96
127.29
108.18%
AXSM
Axsome Therapeutics
213.67
102.54
92.27%
RYTM
Rhythm Pharmaceuticals
115.48
17.39
17.73%
RVMD
Revolution Medicines
203.71
167.26
458.88%
LEGN
Legend Biotech
20.37
-17.08
-45.61%
Corcept Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Corcept Therapeutics Raises 2026 Revenue Outlook on Momentum
Positive
Jul 29, 2026
In the quarter ended June 30, 2026, Corcept Therapeutics reported revenue of $256.1 million, up 32 percent from the same period in 2025, with strong contributions from Korlym and its authorized generic, and $47.6 million from Lifyorli in its first...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Corcept Resubmits FDA Application for Relacorilant in Cushing’s
Positive
Jun 17, 2026
On June 17, 2026, Corcept Therapeutics said it had resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome, following an agency request for additional...
Legal Proceedings
Corcept Faces Amended Qui Tam Complaint After DOJ Exit
Negative
Jun 3, 2026
On May 19, 2026, Corcept Therapeutics learned that the U.S. Department of Justice had filed a Notice of Election to Decline Intervention in a civil qui tam action brought in 2017 by a former employee in the District of New Jersey. The case involve...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Corcept stockholders approve expanded incentive plan and board
Positive
May 28, 2026
On May 21, 2026, Corcept Therapeutics held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the company’s 2024 Incentive Award Plan, increasing the share pool by 8,000,000 and updating plan language, with ...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth
Positive
Apr 30, 2026
On April 30, 2026, Corcept Therapeutics reported first quarter 2026 revenue of $164.9 million, up from $157.2 million a year earlier, but posted a net loss of $31.8 million versus prior net income as operating expenses climbed to $214.5 million on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.